Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 21 07 2021
accepted: 08 11 2021
pubmed: 15 12 2021
medline: 15 1 2022
entrez: 14 12 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces T cell, B cell, and Ab responses that are detected for several months in recovered individuals. Whether this response resembles a typical respiratory viral infection is a matter of debate. In this study, we followed T cell and Ab responses in 24 mainly nonhospitalized human subjects who had recovered from PCR-confirmed SARS-CoV-2 infection at two time points (median of 45 and 145 d after symptom onset). Ab responses were detected in 95% of subjects, with a strong correlation between plasma and salivary anti-spike (anti-S) and anti-receptor binding domain IgG, as well as a correlation between circulating T follicular helper cells and the SARS-CoV-2-specific IgG response. T cell responses to SARS-CoV-2 peptides were determined using intracellular cytokine staining, activation markers, proliferation, and cytokine secretion. All study subjects had a T cell response to at least one SARS-CoV-2 Ag based on at least one T cell assay. CD4

Identifiants

pubmed: 34903642
pii: jimmunol.2100727
doi: 10.4049/jimmunol.2100727
doi:

Substances chimiques

Immunoglobulin G 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-443

Informations de copyright

Copyright © 2022 by The American Association of Immunologists, Inc.

Auteurs

Jaclyn C Law (JC)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Melanie Girard (M)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Gary Y C Chao (GYC)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Lesley A Ward (LA)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Baweleta Isho (B)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Bhavisha Rathod (B)

Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.

Karen Colwill (K)

Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.

Zhijie Li (Z)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

James M Rini (JM)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.

Feng Yun Yue (FY)

Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Samira Mubareka (S)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Sunnybrook Research Institute, Toronto, Ontario, Canada; and.

Allison J McGeer (AJ)

Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Mario A Ostrowski (MA)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Keenan Research Centre for Biomedical Science, St. Michael's Hospital, UnityHealth, Toronto, Ontario, Canada.

Jennifer L Gommerman (JL)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Anne-Claude Gingras (AC)

Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Tania H Watts (TH)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada; tania.watts@utoronto.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH